Company intelligence / Profile preview

Isofol Medical

Ownership: Private
Development stage: Phase 3

Overview

Isofol’s lead candidate arfolitixorin is a novel folate-based compound designed to enhance the efficacy of 5-FU-based chemotherapy. A global Phase III trial in metastatic colorectal cancer did not meet its primary endpoint, but preclinical and clinical data suggest dose-dependent activity. The company is now conducting a new Phase Ib/II study with an optimized dosing regimen to further evaluate efficacy and safety in first-line metastatic colorectal cancer patients.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

arfolitixorin

Partnerships

Solasia Pharma K.K. – rights to arfolitixorin/SP‑05 in Japan, resumed development as of March 2024.

Beyond the preview

Go deeper on Isofol Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Isofol Medical.